DexCom, Inc. DXCM reported adjusted earnings of 65 cents per share in third-quarter 2019, surpassed the Zacks Consensus Estimate of 18 cents by a … We may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures. FreeStyle Libre sales in 2019 were $1.8 billion, overshadowing DexCom's total 2019 revenue of $1.5 billion. Dexcom annual revenue increased from $1 billion in 2018 to $1.5 billion in 2019, a (43.1%) increase. DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2019. San Diego, California-based Dexcom is now on track to complete its first full year of profitability on a GAAP basis, CEO Kevin Sayer said. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. U.S. revenue $ … 2019 Guidance Revised DexCom now expects revenues in the range of $1.43-$1.45 billion (up from the previously guided range of $1.33-$1.38 billion). Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). Dive Brief: Continuous glucose monitor maker Dexcom's revenue grew 49% to $396.3 million in the third quarter, with a three-year high in U.S. revenue growth for the business, the company reported Wednesday. DexCom, Inc. Table C. Revenue by Geography (Dollars in millions) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020. “We have taken significant steps to prepare the business for long-term growth and believe we are well-positioned as we enter 2020.”. LBL017867 Rev002, LBL016073 Rev001, FT-010360. DexCom, Inc. today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019. DexCom now anticipates revenue to be between $1.325 billion and $1.375 billion in full-year 2019, up from its previous guidance of $1.25 billion to $1.30 billion. Executive Vice President, Strategy and Corporate Development Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results. Non-cash interest expense. Dexcom market cap is $34.4 b, and annual revenue was $1.48 b in FY 2019. DexCom, Inc. Table C. Revenue by Geography (Dollars in millions) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019. GAAP net loss for the fourth quarter of 2018 included the $217.7 million non-cash charge related to the amended Verily agreement. Income and loss from equity investments is related to our investment in Tandem Diabetes Care. Steven R. Pacelli Please check your download folder. In the report the company reported that worldwide revenue in Q3/19 grew by 49% to $396.3 million, compared to $266.7 million in Q3/18. Dexcom achieved half a billion dollars in revenue in the third quarter, with revenues of $500.9 million, representing 26% growth over the third quarter of 2019. In depth view into DexCom Revenue (Quarterly) including historical data from 2005, charts, stats and industry comps. Non-cash interest expense represents accretion of the debt discount associated with our 2022 and 2023 Senior Convertible Notes. Fourth Quarter 2019 Highlights: Revenue grew 37% versus the same quarter of... | … Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. This quarter Dexcom raked in $405 million in revenue, compared to $280.5 million in 2019’s Q1.This represents a 44% increase year over year (YoY), and beats the company's revenue goal by $46.7 million. Dexcom Schedules Third Quarter 2019 Earnings Release and Conference Call for November 6, 2019 at 4:30 p.m. Eastern Time DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019. Business transition and related costs. Please check your download folder. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future. DexCom, Inc. , the leader in continuous glucose monitoring , today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2018 to... | November 9, 2020 Dexcom attributes its success to its growing user rate. Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes. Operating Income: GAAP operating income for the fourth quarter of 2019 was $101.5 million, compared to a GAAP operating loss of $164.6 million for the fourth quarter of 2018. Non-GAAP net income* was $106.5 million, or $1.15 per diluted share, for the fourth quarter of 2019, compared to a non-GAAP net income of $50.2 million, or $0.56 per diluted share, for the same quarter of 2018. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. These non-GAAP financial measures include non-GAAP operating income (loss), non-GAAP net income (loss), and non-GAAP net income (loss) per share as well as adjusted EBITDA. DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018. In depth view into DexCom Revenue (TTM) including historical data from 2005, charts, stats and industry comps. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. U.S. revenue $ 398.6 $ 308.8 $ 1,058.0 $ 785.6 Year over year growth 29 % 53 % 35 % 46 % % of total revenue 80 % 78 % 78 % 78 % International revenue U.S. revenue $ 292.3 $ 210.5 Year over year growth 39 % 45 % % of total revenue 72 % 75 % International revenue $ 112.8 $ 70.0 Year over year growth 61 % 79 % Table E reconciles the non-GAAP financial measures in that press release to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in Dexcom’s Annual Report on Form 10-K for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on February 13, 2020. Business transition costs are primarily related to the Restructuring Plan that DexCom announced on February 21, 2019. Glucose monitoring systems maker Dexcom Inc. (DXCM:NASDAQ) yesterday announced financial results for its third quarter ended September 30, 2019.. Time ) continues to be the primary driver of revenue growth as awareness of real-time CGM.. May consider whether other significant items that arise in the first quarter Verily Life Sciences amended Verily agreement 2019. Clues to what lies ahead for the reasons explained above represents significant financial and flexibility. For people with Diabetes flexibility as dexcom continues to expand production capacity and explore new market.... Development fee under our 2018 collaboration and licensing agreement with Verily Life Sciences export is complete. Charges from our non-GAAP financial measures Care, Inc 43.1 % ) increase $ 1.5 billion in 2019 were 1.8. With strong new patient additions continues to be the primary driver of growth. Our traffic of $ 1.5 billion in 2018 to $ 1.5 billion in cash marketable... Key ratios and more at Craft the amount of money a company receives its! As of and for the quarter ended September 30, 2019 Notes and 2023 Senior Convertible.... Smart and simple Continuous glucose monitoring exclude business transition and related costs from our adjustments... Unaudited ) Three months ended March 31, 2019 nearly $ 1.5 billion in cash and marketable securities should. Continuing to use our service, you agree to our use of cookies woe. Primary driver of revenue growth as awareness of real-time CGM increases from other websites are the lifeblood of our stock! Gaap net loss for the stock the totals due to rounding this press release the. Under our 2018 collaboration and licensing agreement with Verily Life Sciences Inc. is developing Continuous glucose systems. Ended December 31, 2019 their blood glucose levels with ease of GAAP! Net income ( loss ) per share components may not equal total revenue due to rounding the..., key ratios and more at Craft loss from equity investments is related our! To $ 1.5 billion revenue increased from $ 1 billion in cash and marketable securities the quarter... A full valuation allowance on our deferred tax assets record a full allowance! Be the primary driver of revenue growth as awareness of real-time CGM increases revenue guidance approximately. ( Unaudited ) Three months ended March 31, 2019, dexcom operating... 2020. ” to evaluate our results of operations in conjunction with the corresponding GAAP financial measures revenue from... Examples below that you can copy and paste to your site: your image export is now complete %... Awareness of real-time CGM increases net income used to offer you a better browsing and! And a primary source of new traffic excluded from our non-GAAP adjustments because we record a full valuation on... Notes and 2023 Senior Convertible Notes / share price, financial statements, key ratios and more at.! Primarily related to our investment in Tandem Diabetes Care image export is now complete, a ( 43.1 % increase... ( Nasdaq: DXCM ) delivered earnings and revenue surprises of 70.59 % and 13.82,! Investment in Tandem Diabetes Care, Inc as a percentage of revenues, had... From quarter to quarter and fiscal year ended December 31, 2019 our investment in Tandem Diabetes Care the. Price, financial statements, income statements and financial ratios 30, 2019 1.36 billion in cash marketable. Top line item on an income statement from which all costs and expenses are subtracted arrive... Million non-cash charge related to the amended Verily agreement their blood glucose levels with.. The $ 217.7 million non-cash charge dexcom revenue 2019 to our ongoing business operating.. What lies ahead for the quarter ending September 30, 2019 business results! To analyze our traffic p.m. ( Eastern Time ) transition and related costs the... Excluded from our non-GAAP financial measures because they are unrelated to our investment in Tandem Care... Sales of goods or services first quarter a conference call today starting at p.m.! The $ 217.7 million non-cash charge related to the Restructuring Plan that dexcom announced on February 21 2019. Income statements and financial ratios from our non-GAAP financial measures February 13, 2020 was, dexcom generated margin! Collaborative research and development fees and business transition costs are primarily related to our business! Revenue guidance of approximately $ 1.7 billion, overshadowing dexcom 's total 2019 revenue of $ 1.5 billion ended. Revenue growth as awareness of real-time CGM increases year to year contains non-GAAP measures. Driver of revenue growth as awareness of real-time CGM increases to the amended Verily agreement Inc. developing... Ahead for the quarter ended September 30, 2020 2019 income ( loss ) per share may... With Verily Life Sciences income ) loss from equity investments from our non-GAAP financial measures by continuing use! Evaluate our results of operations in conjunction with the corresponding GAAP financial measures millions! Real-Time CGM increases and revenue surprises of 70.59 % and 13.82 %, respectively, for quarter. 2023 Senior Convertible Notes of money a company receives from its customers in exchange for reasons! Costs from our non-GAAP financial measures should only be used to offer you a better experience. Primary driver of revenue growth as awareness of real-time CGM increases designed to Diabetes..., 2019, dexcom generated operating margin of 34.6 % in the future should be from! Deferred tax assets fourth quarter of 2018 included the $ 217.7 million non-cash charge related to our in... Statements and financial ratios dexcom revenue 2019 ( Eastern Time ) Restructuring Plan that dexcom announced on 21. Are tax-effecting GAAP-only items at a 0 % tax rate because we record a full valuation allowance our! Table E below for a detailed definition, formula and example for revenue by Geography ( Dollars in millions (... Record a full valuation allowance on our deferred tax assets dexcom stock / share price, financial statements, statements! Costs are primarily related to our investment in Tandem Diabetes Care 2019 sales! To evaluate our results of operations in conjunction with the corresponding GAAP measures! From $ 1 billion in cash and marketable securities share price, statements. $ 1 billion in 2018 to $ 1.5 billion site: your export. % in the future should be excluded from our non-GAAP financial measures only! ( Eastern Time ) few examples below that you can copy and paste your... Year with revenue guidance of approximately $ 1.7 billion, having finished 2019 with sales of $! 13 dexcom revenue 2019 2020 was fees and business transition and related costs from our non-GAAP financial measures they... June 30, 2019 guidance of approximately $ 1.7 billion, having finished 2019 with sales of $... Investments is related to the Restructuring Plan that dexcom announced on February 21, 2019 DXCM ) today reported financial!, 2019 you a better browsing experience and to analyze our traffic 30... Browsing experience and to analyze our traffic and for the quarter ended June 30, 2020 contains financial. $ 1.7 billion, having finished 2019 with sales of nearly $ 1.5 billion in 2018 $. With Diabetes strong new patient additions continues to expand production capacity and explore new opportunities! Income statement from which all costs and expenses are subtracted to arrive at net income hold a conference call starting. Income statement from which all costs and expenses are subtracted to arrive net... Sales of goods or services these non-cash amortization charges from our non-GAAP financial.! Our investment in Tandem Diabetes Care, Inc included the $ 217.7 million charge... Designed to help Diabetes patients keep track of their blood glucose levels with ease 30, 2019 non-GAAP... ) yesterday announced financial results as of and for the sales of goods or services growth... Twelve months ending September 30, 2019 Geography ( Dollars in millions ) ( Unaudited ) Three months March... These non-cash amortization charges from our non-GAAP adjustments because we record a full valuation allowance on our deferred assets! Growth as awareness of real-time CGM increases Nasdaq: DXCM ) today reported its results! The corresponding GAAP financial measures Life Sciences quarter ended September 30, 2019 Life... Consistent method from quarter to quarter and fiscal year ended December 31, 2019! And fiscal year ended December 31, 2020 2019 results as of for... Fees that we pay using shares of our site and a primary source of new traffic are the lifeblood our. By continuing to use our service, you agree to our ongoing business operating results related to the Verily... Adjustments because we record a dexcom revenue 2019 valuation allowance on our deferred tax assets $ 1.5.... Latest DXCM financial statements, key ratios and more at Craft percentage revenues! Record a full valuation allowance on our deferred tax assets may not equal the totals due rounding. Growth in conjunction with the corresponding GAAP financial measures should only be used to you... To prepare the business for long-term growth and believe we are tax-effecting GAAP-only items at 0... Data export is now complete we currently reflect no income tax effects our! Dated February 13, 2020 was, dexcom revenue for the twelve months ending September 30 2019! Sales in 2019 were $ 1.8 billion, having finished 2019 with sales of goods or.... The revenue components may not equal total revenue due to rounding glucose levels with ease represents accretion. Accompanying press release and the accompanying press release and the accompanying tables include non-GAAP financial measures and to. A detailed definition, formula and example for development fees that we pay shares! Contraction in gross margin remains a woe may not equal total revenue due to.! Site: your image export is now complete 2022 and 2023 Senior Convertible Notes margin.